Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.875 GBX | +1.80% | +8.52% | -5.95% |
03-26 | Scancell doses first patient in melanoma-focused trials | AN |
03-22 | Seneca Growth Capital announces tepid 2023 results | AN |
Valuation
Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 20.36 | 37.93 | 179.3 | 116.2 | 128.1 | 80.96 | - | - |
Enterprise Value (EV) 1 | 15.8 | 34.35 | 153.4 | 95.62 | 108.9 | 84.83 | 95.9 | 104.3 |
P/E ratio | -3.62 x | -6.74 x | -9.65 x | -57 x | -10.4 x | -5.39 x | -6.42 x | -6.44 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 24.3 x | - | - | - |
EV / Revenue | - | - | - | - | 20.7 x | - | - | - |
EV / EBITDA | -2.36 x | -5.1 x | -17.9 x | -7.61 x | -9.88 x | -4.92 x | -6.84 x | -7.4 x |
EV / FCF | - | - | - | -8.34 x | -13.1 x | -5.82 x | -8.47 x | -9.64 x |
FCF Yield | - | - | - | -12% | -7.66% | -17.2% | -11.8% | -10.4% |
Price to Book | - | - | - | - | - | -7.38 x | -3.84 x | -2.52 x |
Nbr of stocks (in thousands) | 387,797 | 465,356 | 815,219 | 815,219 | 818,403 | 819,823 | - | - |
Reference price 2 | 0.0525 | 0.0815 | 0.2200 | 0.1425 | 0.1565 | 0.0970 | 0.0970 | 0.0970 |
Announcement Date | 20/08/19 | 16/10/20 | 29/10/21 | 28/10/22 | 31/10/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 5.271 | - | - | - |
EBITDA 1 | -6.708 | -6.739 | -8.585 | -12.56 | -11.02 | -17.23 | -14.01 | -14.11 |
EBIT 1 | -6.729 | -6.782 | -8.834 | -13.3 | -11.92 | -18.03 | -14.86 | -14.94 |
Operating Margin | - | - | - | - | -226.14% | - | - | - |
Earnings before Tax (EBT) 1 | -6.714 | -6.768 | -16.8 | -3.768 | -14.3 | -15.82 | -16.32 | -16.72 |
Net income 1 | -5.627 | -5.506 | -15.48 | -2.065 | -11.94 | -14.78 | -14.37 | -14.8 |
Net margin | - | - | - | - | -226.45% | - | - | - |
EPS 2 | -0.0145 | -0.0121 | -0.0228 | -0.002500 | -0.0150 | -0.0180 | -0.0151 | -0.0151 |
Free Cash Flow 1 | - | - | - | -11.46 | -8.343 | -14.58 | -11.32 | -10.83 |
FCF margin | - | - | - | - | -158.28% | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20/08/19 | 16/10/20 | 29/10/21 | 28/10/22 | 31/10/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | 3.88 | 14.9 | 23.4 |
Net Cash position 1 | 4.56 | 3.58 | 25.9 | 20.5 | 19.2 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | -0.2249 x | -1.066 x | -1.658 x |
Free Cash Flow 1 | - | - | - | -11.5 | -8.34 | -14.6 | -11.3 | -10.8 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | - | -0.0100 | -0.0300 | -0.0400 |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0 | 0.03 | 0.74 | 1.27 | 0.2 | 0.1 | 0.1 | - |
Capex / Sales | - | - | - | - | 3.85% | - | - | - |
Announcement Date | 20/08/19 | 16/10/20 | 29/10/21 | 28/10/22 | 31/10/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.95% | 99.51M | |
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |
- Stock Market
- Equities
- SCLP Stock
- Financials Scancell Holdings plc